Cargando…
SAT-475 New Breast Cancer Therapy Atezolizumab, Leads to Thyroiditis
Background: A NSABP B 59 trial is currently underway to check the efficacy of an experimental drug, Atezolizumab (Anti-PDL 1 monoclonal antibody) in the treatment of triple negative breast cancer. In the trail, the drug is added to the usual neoadjuvant chemotherapy given before surgery and prolonge...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207941/ http://dx.doi.org/10.1210/jendso/bvaa046.1074 |